The effects of recombinant human erythropoietin (r-HuEPO) administration on adequacy of hemodialysis (HD) during single-use versus multiple reuse of hemophan hollow-fiber dialyzers were assessed in 16 stable end-stage renal disease (ESRD) patients. After 12 months of r-HuEPO treatment and maintenance HD with low-flux single-use dialyzers, in the same group of ESRD patients the effectiveness of automated dialyzer reprocessing using peroxyacetic acid was evaluated. Comparison between r-HuEPO-treated patients dialyzed with single-use devices and those treated with reused dialyzers revealed no significant differences in urea kinetic modelling and nutritional status. However, the duration of HD and heparin dosage were significantly (p < 0.05) increased, and the number of dialyzer uses was properly limited during the reuse program. When dialyzer reprocessing was performed, the r-HuEPO dosage and hemoglobin level remained unchanged if compared with the subgroup treated with single-use dialyzers. It was demonstrated that r-HuEPO treatment did not affect the adequacy of HD, even in case of dialyzer reuse.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.